Literature DB >> 27347125

Low expression of secreted frizzled-related protein 2 and nuclear accumulation of β-catenin in aggressive nonfunctioning pituitary adenoma.

Youtu Wu1, Jiwei Bai2, Linchuan Hong1, Chunhui Liu1, Shengyuan Yu1, Guoqiang Yu1, Yazhuo Zhang1.   

Abstract

The identification of a specific molecular marker for aggressiveness of nonfunctioning pituitary adenomas (NFPAs) is urgently required in order to guide the clinical diagnosis and treatment of NFPAs. In the present study, low expression of secreted frizzled-related protein 2 (sFRP2) in NFPAs was demonstrated by reverse transcription-quantitative polymerase chain reaction, western blot and immunohistochemical analyses. The results confirmed an abnormal accumulation of free β-catenin in the nuclei of NFPAs, which is the core step for the activation of the Wnt canonical signaling pathway. Furthermore, cyclin D1 and c-Myc, the downstream proteins of the Wnt canonical signaling pathway, were overexpressed in aggressive NFPAs. These findings demonstrated the activation of the Wnt canonical signaling pathway in aggressive NFPAs. In addition, sFRP2 expression was observed to be inversely correlated to the aggressiveness of NFPAs. Therefore, sFRP2 may act as a tumor suppressor through modulation of the cellular cytosolic pool of β-catenin in NFPAs. Furthermore, the expression of sFRP2 may serve as a biomarker for NFPAs aggressiveness and prognosis.

Entities:  

Keywords:  Wnt canonical signaling pathway; nonfunctioning pituitary adenoma; secreted frizzled-related protein 2; β-catenin

Year:  2016        PMID: 27347125      PMCID: PMC4906981          DOI: 10.3892/ol.2016.4560

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  [Microadenomas and hypersecreting pituitary adenomas].

Authors:  J L Vézina; J Hardy; M Yamashita
Journal:  Arq Neuropsiquiatr       Date:  1975-06       Impact factor: 1.420

Review 2.  Secreted and transmembrane wnt inhibitors and activators.

Authors:  Cristina-Maria Cruciat; Christof Niehrs
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

Review 3.  Radiation therapy in the multimodal treatment approach of pituitary adenoma.

Authors:  Gerd Becker; Martin Kocher; Rolf-Dieter Kortmann; Frank Paulsen; Branislav Jeremic; Rolf-Peter Müller; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2002-04       Impact factor: 3.621

4.  Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.

Authors:  Carmen J Marsit; Margaret R Karagas; Angeline Andrew; Mei Liu; Hadi Danaee; Alan R Schned; Heather H Nelson; Karl T Kelsey
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 5.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

6.  MicroRNA-222 promotes tumorigenesis via targeting DKK2 and activating the Wnt/β-catenin signaling pathway.

Authors:  Qifeng Li; Ke Shen; Yang Zhao; Xiaoguang He; Chenkai Ma; Lin Wang; Baocheng Wang; Jianwen Liu; Jie Ma
Journal:  FEBS Lett       Date:  2013-04-12       Impact factor: 4.124

Review 7.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

8.  SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.

Authors:  Ming-Tzeung Chung; Hung-Cheng Lai; Huey-Kang Sytwu; Ming-De Yan; Yu-Lueng Shih; Cheng-Chang Chang; Mu-Hsien Yu; Hang-Seng Liu; Da-Wei Chu; Ya-Wen Lin
Journal:  Gynecol Oncol       Date:  2008-12-18       Impact factor: 5.482

Review 9.  Wnt signalling in pituitary development and tumorigenesis.

Authors:  T J G Chambers; A Giles; G Brabant; J R E Davis
Journal:  Endocr Relat Cancer       Date:  2013-05-20       Impact factor: 5.678

10.  Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer.

Authors:  Y Y Cheng; J Yu; Y P Wong; E P S Man; K F To; V X Jin; J Li; Q Tao; J J Y Sung; F K L Chan; W K Leung
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

View more
  6 in total

1.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

Review 2.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

3.  Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.

Authors:  Zhiming Zheng; Yongchao Zhang; Zhen Zhang; Yihang Yang; Tao Song
Journal:  Med Sci Monit       Date:  2017-03-13

4.  Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling.

Authors:  Jie Ren; Fangfang Jian; Hong Jiang; Yuhao Sun; Sijian Pan; Changwei Gu; Xiao Chen; Weiqing Wang; Guang Ning; Liuguan Bian; Qingfang Sun
Journal:  Int J Oncol       Date:  2018-04-03       Impact factor: 5.650

5.  Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas.

Authors:  Ying Long; Miaolong Lu; Tingting Cheng; Xiaohan Zhan; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-17       Impact factor: 5.555

Review 6.  Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis.

Authors:  Karlijn van Loon; Elisabeth J M Huijbers; Arjan W Griffioen
Journal:  Cancer Metastasis Rev       Date:  2020-11-02       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.